Related Experiment Video
Updated: Jul 26, 2025
04:20
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
974
SLC5A3 is important for cervical cancer cell growth
Li Li1, Fang-Rong Shen2, Qunxian Cheng1
1Department of Obstetrics and Gynecology, Minhang Hospital, Fudan University, Shanghai, China.
International Journal of Biological Sciences
|June 16, 2023
Summary
The myo-inositol transporter SLC5A3 is overexpressed in cervical cancer, promoting tumor growth and reducing patient survival. Inhibiting SLC5A3 offers a potential new therapeutic strategy for cervical cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cervical cancer necessitates novel molecular targets for effective treatment.
- The role of myo-inositol transporter SLC5A3 in cervical cancer pathogenesis is largely unexplored.
Purpose of the Study:
- To investigate the role of SLC5A3 in cervical cancer development and progression.
- To evaluate SLC5A3 as a potential therapeutic target for cervical cancer.
Main Methods:
- Bioinformatic analysis of SLC5A3 mRNA levels in cervical cancer tissues.
- In vitro studies using SLC5A3 knockdown/knockout in cervical cancer cells.
- In vivo studies involving cervical cancer xenografts in mice.
- Analysis of myo-inositol levels, oxidative stress, and Akt-mTOR signaling.
Main Results:
- SLC5A3 mRNA levels are upregulated in cervical cancer and correlate with poor prognosis.
- SLC5A3 knockdown/knockout inhibits cancer cell growth, induces apoptosis, and reduces myo-inositol levels.
- SLC5A3 overexpression enhances proliferation and migration, linked to Akt-mTOR activation.
- In vivo, SLC5A3 inhibition via shRNA or knockout significantly reduces tumor growth.
Conclusions:
- Overexpressed SLC5A3 drives cervical cancer cell proliferation and migration.
- SLC5A3 represents a promising novel oncotarget for cervical cancer therapy.
